

Neutrophil to Lymphocyte Ratio (NLR) Predicts Local Control Failure and Overall Survival after Stereotactic Body Radiotherapy (SBRT) in Metastatic Sarcoma

Eashwar Somasundaram

Case Western Reserve University School of Medicine

Timothy D Smile

Cleveland Clinic

Ahmed Halima

Cleveland Clinic

James B Broughman

Cleveland Clinic

Chandana A Reddy

Cleveland Clinic

Shireen Parsai

Ohio Health Riverside Methodist Hospital

Jacob G Scott

Cleveland Clinic

Timothy Chan

Cleveland Clinic

Shauna Campbell

Cleveland Clinic

Lilyana Angelov

Cleveland Clinic

Stacey Zahler

Cleveland Clinic

Matteo Trucco

Cleveland Clinic

Stefanie M Thomas

Cleveland Clinic

Shavaughn Johnson

Cleveland Clinic

Peng Qi

Cleveland Clinic

Anthony Magnelli

Cleveland Clinic

Peter M. Anderson

Cleveland Clinic

Erin S. Murphy (✉ murphye3@ccf.org)

Cleveland Clinic

Article

Keywords: neutrophil to lymphocyte ratio (NTLR), absolute lymphocyte count (ALC), stereotactic body radiotherapy (SBRT), sarcoma, radiation, cancer immunity, tumor inhibitory microenvironment

Posted Date: June 8th, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-2570832/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

The neutrophil to lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) recovery are prognostic across many cancers. We investigated whether NLR predicts SBRT success or survival in a metastatic sarcoma cohort treated with SBRT from 2014 and 2020 (N = 42). Wilcoxon Signed Rank Test and Friedman Test compare NLR changes with local failure vs. local control (N = 138 lesions). Cox analyses identified factors associated with overall survival. If local control was successful, NLR change was not significant ($p = 0.30$). However, NLR significantly changed in patients local failure ($p = 0.027$). The multivariable Cox model demonstrated higher NLR before SBRT was associated with worse overall survival ($p = 0.002$). The optimal NLR cut point was 5 (Youden index: 0.418). One-year overall survival in SBRT metastatic sarcoma cohort was 47.6% (CI 34.3%-66.1%). Patients with an NLR above 5 had a one-year overall survival of 37.7% (21.4%-66.3%); patients with an NLR below 5 had a significantly improved overall survival of 63% (43.3%-91.6%, $p = 0.014$). Since NLR at the time of SBRT was significantly associated with local control success and overall survival in metastatic sarcoma treated with SBRT, future efforts to reduce tumor inhibitory microenvironment factors and improved lymphocyte recovery should be investigated.

INTRODUCTION

Sarcomas are a group of rare mesenchymal tumors that account for less than 1% of adult solid malignancies, but represent 21% of pediatric solid malignancies¹. While the incidence is low relative to other malignancies, their biological heterogeneity and relative treatment resistance have made sarcomas challenging to treat². Sarcomas can be divided into soft tissue sarcomas and sarcomas associated with bone primary tumors (e.g. osteosarcoma and Ewing sarcoma). Advances in sarcoma staging and therapy have led to survival improvements in both classes of sarcomas as well as improved risk-stratification³. For example, the 5-year survival in rhabdomyosarcoma has improved from around 50–70%.⁴ Advancements in chemotherapy have improved prognosis in patients with low grade tumors. However, the success of surgery, radiotherapy, and chemotherapy capable of treating advanced metastatic disease is low^{5,6}. Many patients present with high-grade histopathological features, and up to 25% of patients present with distant metastasis^{3,4}. The current standard of care for most sarcomas is a combination of chemotherapy and local control that includes surgical resection and/or radiotherapy. Radiation is typically reserved for unresectable disease, when surgical morbidity could limit function, or when metastases are present⁷. There is an unmet need for more data to improve quality of cancer care and survival⁸.

Stereotactic body radiation (SBRT) is a relatively new advancement in radiotherapy that uses image guidance to precisely deliver high doses of ablative radiation in fewer fractions compared to traditional dose regimens. While contemporary indications for SBRT are rapidly expanding, it is most commonly used to treat inoperable early stage non-small cell lung cancer, prostate cancer, unresectable pancreatic cancer, pulmonary and hepatic metastases, and metastases to the spine or brain via a stereotactic

radiosurgery approach⁹. Some sarcomas are relatively radio-resistant—that is, resistant to conventionally fractionated radiotherapy without concurrent chemotherapy—and would theoretically benefit from the high biologically equivalent doses (BED) accompanying SBRT regimens. A multi-institutional phase II trial showed a 95% rate of lesion-specific local control at 6 months and improved progression free survival (PFS) and OS in patients with unresectable metastatic sarcoma treated with SBRT¹⁰. While local control with SBRT is encouraging, careful consideration of the therapeutic window must be applied as the higher fractional doses of radiation from SBRT increase the risk of developing late complications in normal tissue. A retrospective analysis of 31 patients found similarly high rates of local control and minimal toxicity, with only 1 out of 31 patients experiencing a late grade 3 radiation related toxicity¹¹. SBRT has typically been reserved as salvage therapy for treatment resistant disease, so its role in primary treatment remains unknown, but has been investigated on a large cohort in a completed Children’s Oncology Group clinical trial in patients with metastatic Ewing sarcoma (NCT02306161).

Another recent advancement in oncology is our understanding about the role of the immune system in cancer. Malignant cancer cells can produce neoantigens that are recognized by the immune system as “not self.” Cytotoxic T-cells can identify tumor cells through these foreign antigens and initiate immune-mediated tumor cell death¹². Interestingly, it has been shown that tumors with higher mutational burden can express tumor-associated neoantigens that lead to a better response to immunotherapy^{13, 14}. In June 2020, the Food and Drug Administration (FDA) approved the use of immune checkpoint inhibitors (ICIs) in solid tumors of any type with a tumor mutational burden of 10 or more mutations per megabase. A myriad of factors including but not limited to cellular immunity and tumor inhibitory microenvironment affect the immune system’s ability to eradicate cancer¹⁵.

Radiation therapy induces DNA damage through direct interaction and generation of reactive oxygen species. Tumor cells that survive the direct toxicity can express new antigens that may be recognized by the host immune system¹⁶. After radiation induced cell death of cancer cells, neutrophils and lymphocytes are actively recruited to the tumor site¹⁷. Given the interactions between radiation and the immune system, there may be a promising role for immunotherapy and radiotherapy synergism in the treatment of malignancy. SBRT, rather than conventional radiotherapy, may especially be synergistic with the patient’s immune system because it causes less lymphocyte depletion¹⁸. In pediatric osteosarcoma and Ewing sarcoma, improved absolute lymphocyte count (from either lymphocyte resilience or earlier recovery of lymphocytes post chemotherapy) has demonstrated survival benefits^{19–22}. If the immune system is a critical part of the radiation efficacy, it would be helpful to have biometrics that help characterize the state of one’s immune system prior to SBRT.

Currently, there is no gold standard biomarker or biometric that can be used to assess how a patient’s immune system may respond to radiation. The NTLR is a promising candidate that has been correlated with survival in many malignancies including sarcoma before surgery²³ and after chemotherapy²⁴. Elevated pretreatment NTLR have been associated with poorer prognosis in both solid and hematological

malignancies²⁵⁻²⁸. In soft tissue sarcoma, it has been associated with poorer survival and increased risk of distant metastasis²⁹. Lymphopenia is a prognostic factor in advanced sarcomas, too³⁰.

How the NTLR biometric might change with SBRT has not been investigated. While the literature suggests that NTLR will likely be prognostic across cancer diagnoses, it has not been studied in this population of metastatic sarcoma patients treated with SBRT. In this study, we show how NTLR changes over the SBRT treatment course and optimize a NTLR cutoff score to stratify patients with metastatic sarcoma into high and low risk survival groups. Furthermore, we demonstrate high NTLR was associated with a significantly worse prognosis and local control failure after SBRT in patients with metastatic sarcomas.

METHODS

Cohort. This study was approved By the Cleveland Clinic Institutional Review Board (IRB) as a single-institution registry of patients with metastatic sarcoma diagnosed between 2014 and 2020 treated with SBRT. After discussion of indications, risks, benefits, and alternatives, all patients or legal guardians provided written informed consent for SBRT as part of standard clinical care. No additional blood samples were obtained, therefore this was not considered an interventional study requiring additional informed consent for additional research blood samples as per IRB guidelines for a retrospective study. All research was performed in accordance with relevant guidelines and regulations. Included patients had histologically confirmed sarcoma including clear cell sarcoma, desmoplastic small round cell tumor, Ewing sarcoma, myxoid liposarcoma, osteosarcoma, rhabdomyosarcoma, undifferentiated pleomorphic small round blue cell sarcoma, and synovial sarcoma) with at least one metastatic lesion treated with SBRT. CBC with differential data was collected by retrospective chart review at time points prior to SBRT, after SBRT, in follow-up, and at time of progression.

Treatment. Patients with histopathologic diagnosis of sarcoma were treated with SBRT defined as a fractional dose of ≥ 5 Gy delivered in five or fewer fractions to site(s) of metastatic disease. The intent of therapy -usually either definitive for oligo-metastatic disease or palliative for durable local control of metastases—as well as the specific dose and fractionation regimen were determined at the discretion of the treating physician. Technical details of SBRT technique based on lesion location have been described previously^{11, 31}.

Laboratory investigations. For each lesion treated with SBRT, complete blood count (CBC) data before and after SBRT treatment and in follow up were recorded. Since CBC is not routinely measured immediately before or after treatment, we included values within 3 months of treatment. We also recorded CBC parameters collected within 3 months after any local failure. We calculated a neutrophil to lymphocyte ratio by dividing absolute neutrophil count by absolute lymphocyte count. Friedman Test was used to assess changes in NTLR through SBRT therapy in failed lesions (comparing before SBRT vs after SBRT vs after local recurrence). Wilcox signed rank was used to compare NTLR in locally controlled lesions before SBRT versus after SBRT. These nonparametric statistical methods were chosen over linear

regression methods due to the non-normality of the data and limited time points for comparison of the dependent variables.

Imaging. Patients received routine post-treatment imaging follow-up with CT, MRI, or PET to assess for local control. Local tumor failure was defined as recurrence of tumor at treatment site as determined by enlarged lesion on CT, MRI, or PET scan and/or interpretation of the radiologist and tumor board members.

Univariate and multivariate analysis of effects on survival. For each patient, the pretreatment CBC parameters within 3 months of SBRT was averaged and included with averaged values with other clinically relevant variables such as concurrent chemotherapy, Karnofsky Performance Status (KPS), and age in univariate Cox regression models to analyze their impact on overall survival. Overall survival was defined as time to death or last follow up from first treatment date. A selection criterion of $p < 0.15$ from the univariate model was used to determine the variables for the multivariate model. This was done because a small number of covariates was more appropriate for the small population size. Age, mean biologic equivalent dose across treatments, KPS, and NTLR were selected for the multivariate model.

A smoothed time-dependent ROC curve calibrated to 24 months of survival was used to generate an optimal cut point for NTLR³². Each patient's NTLR was the average of their NTLR values prior to each SBRT treatment session. Optimal cut point to stratify patients into high and low risk groups was determined by the NTLR that maximized the Youden index, defined as the sum of sensitivity and specificity minus one. The Kaplan Meier method was used to calculate rates of overall survival. We compared the overall survival for these two groups using the log-rank test. All data were stored in a secure RedCap registry, and all analyses were performed in R (version 3.6.3)³³.

RESULTS

In total, there were 42 patients with 138 lesions that met criteria for the study as detailed in Table 1. The median age at diagnosis was 21 years with a range of 4 to 47 years. The median pretreatment NTLR for the cohort was 5.3. Twenty-five out of 42 patients had confirmed death, and the median clinical follow up time for surviving patients was 24 months and median imaging follow up time was 7.7 months.

Table 1

Patient characteristics. Data is presented as either median [min to max] or as number in category (percent of whole group). NTLR: Neutrophil-to-lymphocyte ratio

	All Patients (n = 42)
Age at Diagnosis (years)	21.5 [4.1, 47.7]
Male Sex (%)	24 (57.1)
Mean Pretreatment NTLR	5.26 [0.46, 29.19]
NTLR Risk Category = low (%)	24 (61.5)
Mean Pretreatment KPS (%)	
<= 70	6 (15.0)
70–80	13 (32.5)
80–90	17 (42.5)
90–100	4 (10.0)
SBRT Treatment Courses	2 [1, 20]
Follow up Time (months)	23.8 [6.0, 35.0]

Details about all individual lesions (n = 138) were recorded in our registry (Table 2). Most sarcomas treated with SBRT were osteosarcoma or Ewing sarcoma (84/138), and the remaining were soft tissue sarcomas. Lesions received 22.2–140 Gy with a median dose of 40 Gy (most common regimen was 8 Gy x 5 fractions) with biological equivalent dose from 66.7 Gy to 419 Gy with a median dose of 117 Gy, using an alpha/beta ratio of 3. Most patients lesions receiving SBRT were also receiving concurrent systemic therapy (79/138, 57%). A total of 34/138 (25%) lesions experienced local recurrence. Figure 1 demonstrates the change in neutrophil to lymphocyte ratio over time. Median NTLR for sarcoma patients with controlled lesions before and after SBRT were very similar: 5.0 (IQR: 2.7–13.4) and 4.8 (IQR: 2.3–9.4), respectively. In patients with the 25% lesions that recurred the median NTLR for before and after SBRT was lower [3.3 (IQR: 2.2–5.0) and 3.5 (IQR: 3.0–6.1), respectively], and at time of local failure was higher [5.6 (IQR: 3.8–5.9)]. For locally controlled lesions, there was no significant difference in NTLR between the before and after SBRT groups (p = 0.30). For lesions that experienced recurrence, there was a significant difference in NTLR amongst the three groups (before, after SBRT and at recurrence: p = 0.027).

Table 2
Descriptive Characteristics of sarcoma lesions treated with SBRT

	All Lesions (n = 138) Median [min-max]
Sarcoma Histology (%)	
Clear cell carcinoma	3 (2.2)
Desmoplastic small round cell tumor	21 (15.3)
Ewing sarcoma	30 (21.9)
Osteosarcoma	54 (39.4)
Paraganglioma	7 (5.1)
Rhabdomyosarcoma	7 (5.1)
Small Round Blue Cell Sarcoma	4 (2.9)
Synovial Sarcoma	11 (8.0)
Biological Equivalent Dose (Gy)	116.70 [66.7- 419.3]
Pretreatment White Blood Cell Count (10 ³ /uL) ¹	5.10 [0.09–15.8]
Pretreatment Hemoglobin (g/dL)	12.1 [7.7, 16.8]
Pretreatment Hematocrit (%)	35.6 [23.8–49.3]
Pretreatment Platelets (10 ³ /uL)	183[11–570]
Pretreatment Absolute Neutrophil Count (10 ³ /uL)	3.2 [0.6–14.5]
Pretreatment Absolute Lymphocyte Count (10 ³ /uL)	0.60 [0.08–3.8]
Pretreatment Lactate Dehydrogenase units/L)	211 [125–671]
Pretreatment Albumin (g/dL)	4.20[2.7, 7.8]
Pretreatment Neutrophil to Lymphocyte Ratio	4.1 [0.5, 72.7]
Received Concurrent Therapy (%) ²	79 (57.2)
Surveillance Follow up Time (months)	7.7 [0.5–35]

¹Pretreatment complete blood count (CBC) data was charted within 3 months of treating the lesion.

²Concurrent therapy includes any chemotherapy or immunotherapy received at time of treatment.

³Local recurrence was determined by CT or PET imaging surveillance. Data is presented as either median [min to max] or as number in category (percent of whole group).

	All Lesions (n = 138)
	Median [min-max]
Sarcoma Histology (%)	
Known Local Recurrences (%)³	34 (28.8)
¹ Pretreatment complete blood count (CBC) data was charted within 3 months of treating the lesion.	
² Concurrent therapy includes any chemotherapy or immunotherapy received at time of treatment.	
³ Local recurrence was determined by CT or PET imaging surveillance. Data is presented as either median [min to max] or as number in category (percent of whole group).	

Table 3 demonstrates the Cox proportional hazards regression analyses for overall survival in our patient population. Higher mean radiotherapy BED (HR: 0.99; 95% CI: 0.98 to 1.00) and higher patient KPS (HR: 0.91; 95% CI: 0.87 to 0.96) were significant protective factors for overall survival whereas higher average pretreatment neutrophil count (HR: 1.24; 95% CI: 1.06 to 1.45) and higher average pretreatment NTLR (HR: 1.11; 95% CI: 1.04 to 1.19) were significantly associated with poorer survival in the univariate model. In the multivariable model, only worse KPS (HR: 0.91; 95% CI: 0.86 to 0.96) and higher average pretreatment NTLR (HR: 1.14; 95% CI: 1.05 to 1.24) were significantly associated with overall survival.

Table 3

Cox proportional hazards analysis of clinical and treatment parameters associated with survival. Average KPS across treatments and pretreatment Neutrophil to Lymphocyte Ratio (NTLR) was the only variable associated with survival in both univariate and multivariate models.

Variable	UV Model HR	p-value	MV Model HR	p-value
Age	0.959 (0.917 to 1)	0.0629	0.952 (0.896 to 1.01)	0.104
Male Sex	1.49 (0.657 to 3.37)	0.341		
Number of SBRT Treatments	1.04 (0.964 to 1.13)	0.3		
Mean Treatment BED	0.987 (0.976 to 0.998)	0.017	0.99 (0.978 to 1)	0.106
Mean KPS	0.911 (0.868 to 0.957)	0.00018	0.912 (0.864 to 0.963)	0.00083
Mean Pretreatment Neutrophil Count	1.24 (1.06 to 1.45)	0.006		
Mean Pretreatment Lymphocyte Count	0.637 (0.312 to 1.3)	0.216		
Mean Pretreatment NTLR	1.11 (1.04 to 1.19)	0.003	1.14 (1.05 to 1.24)	0.0023
Received Concurrent Therapy	1.87 (0.742 to 4.69)	0.185		

Figure 2 demonstrates the time-dependent ROC curve calibrated to 24 months drawn to assess the optimal cutoff for stratifying high vs low risk groups based on NTLR. The optimal pre-SBRT NTLR cut point value was determined to be 5.033, which was rounded down to 5 and used for stratification into high risk and low risk groups. 24 patients (57%) were in the low risk NTLR category (< 5). Kaplan-Meier estimates for overall survival were calculated as shown in Fig. 3. Patients with a high NTLR (≥ 5) had significantly worse survival ($p = 0.014$). Patients with an NTLR ≥ 5 had a 1-year survival of 37.7% (95% CI: 21.4%-66.3%), while patients with an NTLR < 5 had a 1-year survival of 63% (95% CI: 43.3%-91.6%). 1-year survival in the entire cohort was 47.6% (95% CI: 34.3%-66.1%).

DISCUSSION

Our study demonstrated for the first time a significant correlation between increased NTLR and poor local control and significantly worse overall survival in high-risk metastatic sarcoma patients undergoing SBRT. These findings are consistent with the prior observations in non-small cell lung cancer³⁴. Interestingly, patients with lesions with more durable local control after SBRT correlated with a higher baseline NTLR compared to those with lesions that had local failure. However, NTLR in those with lesions that were locally controlled remained stable after therapy and survival seemed to plateau. Among patients

experiencing local failure, the NTLR increased slightly after SBRT and then increased significantly after confirmed sarcoma recurrence. These findings suggest that a rising NTLR may be a sensitive biometric of impending recurrence than absolute elevation of baseline NTLR.

However, absolute NTLR was associated with a significantly worse survival outcome in patients with metastatic sarcoma treated with SBRT. High pretreatment NTLR was associated with poor survival in the multivariable Cox proportional hazards model controlled for age, dose, and KPS. We also calculated a cutoff NTLR value of 5 to risk-stratify patients with metastatic sarcoma into high risk and low risk groups. An elevated NTLR could reflect either inflammation associated with advancing disease, impaired lymphocyte numbers or resilience (i.e. associated with a low ANC); either these immune parameters would be expected to affect the tumor inhibitory microenvironment and be associated with local control failure¹⁵.

In oropharyngeal cancer, an association between loco-regional recurrence and elevated NTLR has been observed³⁵. In the setting of early stage NSCLC patients treated with SBRT, an elevated NTLR predicted for worse survival, but there was no correlation with local control³⁴. This study did not assess changes in NTLR over time, but only evaluated pretreatment variables collected within 2 months of SBRT. Our analysis did not yield a statistical association between time to local recurrence and NTLR prior to treatment in a Kaplan-Meier model; however, our findings may be limited by the sample size of our study.

NTLR may become a useful biometric to study during immunotherapy with radiation, especially SBRT. The potential synergy between radiotherapy and immunotherapy is a growing area of research interest¹⁵. While radiation can result in temporary immunosuppression, it can assist the immune system long term by reducing tumor burden via direct cytotoxicity and exposing neoantigens to the immune system. The induction of neoantigens by radiotherapy and subsequent immunization against those neoantigens have been demonstrated in prostate cancer³⁶. SBRT in particular has been demonstrated to stimulate the cellular immune response through enhanced T cell activity, increased antigen presentation, and release of inflammatory cytokines³⁷. SBRT mediated damage of one tumor site can lead to systemic activation of the immune system against neoantigens present in other tumor sites leading to an abscopal effect, which has been demonstrated in some clinical settings³⁷.

An elevated neutrophil count can be observed in chronic inflammatory conditions, including cancer. Tumor production of cytokines such as IL-1 and IL-6 can induce neutrophilia, with higher circulating neutrophil counts at baseline theoretically corresponding with an increased burden of disease³⁸. It has also been shown that increased absolute neutrophil count (ANC) has the potential to suppress cytotoxic T lymphocyte function³⁹. The relative lymphopenia associated with high NTLR may be associated with a poorer host immune response against tumor antigens and thus a poorer prognosis. T cells are necessary for checkpoint inhibition therapies and the anti-cancer cellular therapies using CAR-T and CAR-NK⁴⁰. Taken together, an elevated NTLR suggests an increased burden of disease and an impaired immune response, both of which are poor prognostic factors. In the context of cancer therapy, we believe NTLR is

a relevant biomarker for assessing potential immune responsiveness following radiotherapy and a useful metric for risk-stratification.

Our study has several limitations. Since this study is retrospective, it is difficult to ascertain time course of exactly when SBRT alters the NTLR biometric. Given the disease rarity and relatively recent implementation of SBRT for treatment of metastatic sarcoma, the small sample size of the cohort still represents a large series of SBRT treated lesions¹¹. Additionally, most sarcoma patients undergoing SBRT were heavily pre-treated with systemic therapies, a factor that likely affected the bone marrow and circulating lymphocytes. Although treatments such as granulocyte colony stimulating factor (G-CSF) could confound results, no one in our SBRT cohort received concurrent G-CSF during or immediately after SBRT.

In conclusion, high NTLR at the time of SBRT treatment was prognostic for significantly worse overall survival of patients undergoing SBRT for metastatic sarcoma. A rise in NTLR was also seen at time of local progression. The NTLR biometric may have implications for future sarcoma treatment, pre-and post-SBRT sarcoma surveillance, and future sarcoma and SBRT clinical trial design warranting further investigation.

Abbreviations

Abbreviations			
SBRT	Stereotactic Body Radiation Therapy	KPS	Karnofsky Performance Status
NTLR	Neutrophil to Lymphocyte Ratio	BED	Biological Effective Dose
CBC	Complete Blood Count	UV	Univariate
KM	Kaplan-Meier	MR	Multivariate
HR	Hazard Ratio		

Declarations

AUTHOR CONTRIBUTIONS

Conception and design: Murphy E, Smile T, Parsai S, Broughman J, Halima A

Data collection: Somasundaram E, Smile T, Parsai S, Halima A, Scott JG, Chan T, Campbell S, Angelov L, Anderson PM, Zahler S, Trucco M, Thomas S, Johnson S, Qi P, Magnelli A

Data analysis and interpretation: Somasundaram E, Reddy C, Smile T, Halima A

Manuscript writing: Somasundaram E, Smile T, Halima A, Anderson PM

Final approval of manuscript: All Authors

DATA AVAILABILITY

Anonymized datasets recorded and analyzed during the current study are available from the corresponding author on reasonable request.

CONFLICTS OF INTEREST STATEMENT

The authors have no conflicts to disclose.

ACKNOWLEDGMENTS

The authors appreciate efforts of care coordinators in Pediatric Oncology (Shauna Sartoski and Alyssa Bauer) to assist pediatric and young adult patients getting SBRT. We also acknowledge generous support from The Cleveland Clinic Sarcoma program, Velosano, and the Little Warriors Foundation. Additionally, we acknowledge support from NIH grant R37 CA244613, NIH grant U54 (Radiation Oncology Biology Integration Network), and the American Cancer Society through their Research Scholar Grant.

References

1. Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. *Clin Sarcoma Res.* Oct 4 2012;2(1):14. doi:10.1186/2045-3329-2-14
2. Skubitz KM, D'Adamo DR. Sarcoma. *Mayo Clin Proc.* Nov 2007;82(11):1409-32. doi:10.4065/82.11.1409
3. Bosma SE, Lancia C, Rueten-Budde AJ, et al. Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. *Sci Rep.* Jul 29 2019;9(1):11000. doi:10.1038/s41598-019-46721-8
4. Williams RF, Fernandez-Pineda I, Gosain A. Pediatric Sarcomas. *Surg Clin North Am.* Oct 2016;96(5):1107–25. doi:10.1016/j.suc.2016.05.012
5. Oyama R, Takahashi M, Yoshida A, et al. Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. *Sci Rep.* Jul 5 2017;7(1):4712. doi:10.1038/s41598-017-04967-0
6. Subbiah V, Hess KR, Khawaja MR, et al. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. *Sci Rep.* Oct 17 2016;6:35448. doi:10.1038/srep35448
7. Sangkhathat S. Current management of pediatric soft tissue sarcomas. *World J Clin Pediatr.* Nov 8 2015;4(4):94–105. doi:10.5409/wjcp.v4.i4.94
8. Subbiah V. The next generation of evidence-based medicine. *Nat Med.* Jan 2023;29(1):49–58. doi:10.1038/s41591-022-02160-z
9. Chang BK, Timmerman RD. Stereotactic Body Radiation Therapy: A Comprehensive Review. *American Journal of Clinical Oncology.* 2007;30(6):637–644. doi:10.1097/COC.0b013e3180ca7cb1

10. El-Bared N, Wong P, Wang D. Soft tissue sarcoma and radiation therapy advances, impact on toxicity. *Curr Treat Options Oncol*. May 2015;16(5):19. doi:10.1007/s11864-015-0335-7
11. Parsai S, Sedor G, Smile TD, et al. Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma. *Am J Clin Oncol*. Mar 1 2021;44(3):126–130. doi:10.1097/coc.0000000000000794
12. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes & development*. 2018;32(19–20):1267–1284. doi:10.1101/gad.314617.118
13. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nature Reviews Cancer*. 2019 /03/01 2019;19(3):133–150. doi:10.1038/s41568-019-0116-x
14. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. Apr 3 2015;348(6230):124-8. doi:10.1126/science.aaa1348
15. Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: Building a bridge over troubled waters. *Cell*. Jul 21 2022;185(15):2770–2788. doi:10.1016/j.cell.2022.06.035
16. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. *Int J Mol Sci*. Jan 10 2014;15(1):927–43. doi:10.3390/ijms15010927
17. McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. *Mamm Genome*. Dec 2018;29(11–12):843–865. doi:10.1007/s00335-018-9777-0
18. Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. Mar 1 2016;94(3):571–9. doi:10.1016/j.ijrobp.2015.11.026
19. Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. *Pediatr Blood Cancer*. Dec 1 2010;55(6):1096–102. doi:10.1002/pbc.22673
20. Anderson P. Predicting and facilitating survival of pediatric cancer patients: the ALC story. *Pediatr Blood Cancer*. Dec 1 2010;55(6):1041–2. doi:10.1002/pbc.22715
21. De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. *J Pediatr Hematol Oncol*. Jan 2007;29(1):48–52. doi:10.1097/MPH.0b013e31802d3e3e
22. DuBois SG, Elterman K, Grier HE. Early lymphocyte recovery in Ewing sarcoma. *J Pediatr Hematol Oncol*. May 2007;29(5):351–2. doi:10.1097/MPH.0b013e3180590627
23. Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q. Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. *Biomarkers*. Sep 2012;17(6):539–44. doi:10.3109/1354750X.2012.699554

24. Skubitz KM, Domingo-Musibay E, Lindgren BR, Cheng EY. Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide. *Cancers (Basel)*. Jul 14 2022;14(14)doi:10.3390/cancers14143419
25. Gago-Dominguez M, Matabuena M, Redondo CM, et al. Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. *Scientific Reports*. 2020/08/06 2020;10(1):13203. doi:10.1038/s41598-020-70077-z
26. Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. *Prostate Cancer and Prostatic Diseases*. 2020 /06/01 2020;23(2):220–231. doi:10.1038/s41391-020-0209-3
27. Sebastian N, Wu T, Bazan J, et al. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. *Radiotherapy and Oncology*. 2019/05/01/ 2019;134:151–157. doi:https://doi.org/10.1016/j.radonc.2019.01.032
28. Porrata LF, Ristow KM, Habermann TM, et al. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. *Blood Cancer J*. Apr 19 2013;3(4):e110. doi:10.1038/bcj.2013.8
29. Chan JY, Zhang Z, Chew W, et al. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. *Scientific Reports*. 2018/08/10 2018;8(1):11959. doi:10.1038/s41598-018-30442-5
30. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. *Cancer Res*. Jul 1 2009;69(13):5383–91. doi:10.1158/0008-5472.CAN-08-3845
31. Parsai S, Juloori A, Angelov L, et al. Spine radiosurgery in adolescents and young adults: early outcomes and toxicity in patients with metastatic Ewing sarcoma and osteosarcoma. *J Neurosurg Spine*. Nov 29 2019:1–8. doi:10.3171/2019.9.SPINE19377
32. Beyene KM, El Ghouch A. Smoothed time-dependent receiver operating characteristic curve for right censored survival data. *Statistics in Medicine*. 2020;39(24):3373–3396. doi:https://doi.org/10.1002/sim.8671
33. R Development Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2017.
34. Shaverdian N, Veruttipong D, Wang J, Schae D, Kupelian P, Lee P. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. *Clin Lung Cancer*. Jan 2016;17(1):39–46. doi:10.1016/j.clcc.2015.07.007

35. Young CA, Murray LJ, Karakaya E, Thygesen HH, Sen M, Prestwich RJ. The Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Oropharyngeal Carcinoma Treated with Chemoradiotherapy. *Clin Med Insights Oncol.* 2014;8:81–6. doi:10.4137/cmo.S15476
36. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. *Clin Cancer Res.* Mar 1 2007;13(5):1493–502. doi:10.1158/1078-0432.Ccr-06-1772
37. Popp I, Grosu AL, Niedermann G, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. *Radiotherapy and Oncology.* 2016/08/01 / 2016;120(2):185–194. doi:https://doi.org/10.1016/j.radonc.2016.07.013
38. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Review. *Frontiers in Physiology.* 2018-February-20 2018;9(113)doi:10.3389/fphys.2018.00113
39. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. *J Immunol.* Jan 1985;134(1):230–4.
40. Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. *Blood Advances.* 2020;4(22):5868–5876. doi:10.1182/bloodadvances.2020002547

Figures

Change in Neutrophil to Lymphocyte Ratio Through Treatment




Figure 1

Change in neutrophil-to-lymphocyte ratio through SBRT All data points are within 3 months of the noted time point. The change in median NTLR within the lesion controlled group was not significant ($p = 0.30$, $N=104$) but was significant within the lesion failure group ($p = 0.027$; $N=34$).

Survival Receiver Operator Curve To Determine Optimal NTLR Cutpoint




Figure 2

Receiver operating curve (ROC) for overall survival. The ROC was calibrated for 24 months of survival, and the optimal cut point that maximized sensitivity and specificity was a pre-SBRT NTLR value of 5.033. The Youden Index of .418 was calculated as [sensitivity (0.698) + specificity (0.720)] - 1.

Overall Survival by Neutrophil to Lymphocyte Ratio Category




Figure 3

Kaplan-Meier curve comparing overall survival by NTLR ratio. Patients with an NTLR above 5 (red bottom line, n = 22) had a 1-year survival of 37.7% (95% CI: 21.4%-66.3%), while patients with an NTLR below 5 (teal, top line; n = 17) had a significantly improved 1-year survival of 63% (95% CI: 43.3%-91.6%, p = .014). 2-year survival was reduced to 18.8% (95% CI: 7.08% to 50.2%) for the high NTLR group and remained unchanged at 63% (95% CI: 43.3%-91.6%, p = .014) for the low NTLR group.